Torrent Pharma Reports Strong Q1 FY27 Results, Showing 55% Rise in Total Revenue
Torrent Pharmaceuticals Limited today announced its consolidated financial results for the first quarter of fiscal year (FY) 2027, highlighting robust growth across its domestic and international markets. The company reported total revenue reaching Rs. 4,921 crores, driven by strong performance in both its Base Business and JB Business segments.The Q1 FY27 consolidated results showed the Group achieving a net profit after tax (PAT) of Rs. 566 crores. Operational efficiency remained high, with Operating EBITDA standing at Rs. 1,664 crores for the quarter. The company reported that its Gross Margin stood at 76.4%, while the Op. EBITDA margin was noted at 33.8%.
Segment Performance Overview
Torrent Pharmaceuticals demonstrated diversified growth across its geographical and business segments.The Consolidated Revenue Summary for Q1 FY27 is detailed below:
| Region | Base Business (Rs cr) | JB Business (Rs cr) | Total (Rs cr) | Base Growth (%) | Reported Growth (%) |
|---|---|---|---|---|---|
| India | 2,157 | 733 | 2,890 | 19% | 60% |
| International | 1,451 | 468 | 1,919 | 19% | 57% |
| Others | 112 | - | 112 | -24% | -24% |
| Total | 3,720 | 1,201 | 4,921 | 17% | 55% |
The JB Business alone recorded revenues of Rs. 1,201 crores in Q1 FY27, up 10% compared to Q1 FY26. The International business contributed Rs. 1,919 crores across the Base and JB segments combined.
Key Highlights and Operational Milestones
The company's performance was underpinned by strong regional growth metrics:- India: India revenues reached Rs. 2,157 crores, reflecting a 19% increase compared to market (IPM) growth of 12%. The company holds the #1 ranking in the IPM cardiac market and maintains strong outperformance in this segment. Gx Semaglutide achieved a Q1 FY27 market share of 36% in the oral and injectable combined category, according to AIOCD PharmaTrac data.
- International: International revenues were Rs. 1,451 crores (Base Business) and Rs. 468 crores (JB Business), totaling 1,919 crores. The international market showed a 19% growth in the Base Business segment and a 12% increase in the JB business portfolio.
- Brazil: Revenues stood at Rs. 277 crores, representing a 27% rise. Constant currency revenues were up by 3%, aligning with a 21% growth rate compared to market growth of 5%, according to IQVIA data.
Torrent Pharma also provided updates on the integration of JBCPL into its structure. The amalgamation of JBCPL with the Company, which was approved by the National Company Law Tribunal (NCLT) on July 6, 2026, became effective on January 21, 2026. In line with the scheme, Torrent Pharma allotted 4,19,22,416 fully paid-up equity shares of Rs. 5 each to eligible shareholders of JB Pharma as of July 17, 2026.
Furthermore, the company announced that Ameera Shah will conclude her term as an Independent Director on August 1, 2026.
TORNTPHARM Stock Price Movement
Torrent Pharmaceuticals Limited closed today having edged up to ₹4872.1, settling at a gain of 0.24% in the close. The stock saw a daily traded volume of 790,538 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.